Trial Profile

Neoadjuvant IntraviTreal Ranibizumab treatment in high-risk Ocular melanoma patients: a two-stage single-centre phase II single arm study (NITRO trial)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary)
Indications Uveal melanoma
Focus Therapeutic Use
Acronyms NITRO - Version 1

Most Recent Events

01 Feb 2020 This study was terminated early as alternative treatments were clearly superior for local tumour control as per results published in the Melanoma Research
07 Jun 2018 Status changed to discontinued.
08 Nov 2013 Accrual to date is 28% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com